Jiang J, Patil D, Traore EJ, et al. - The present study was conducted to assess utility of third-line overactive bladder (OAB) treatments including percutaneous tibial nerve stimulation (PTNS), sacral nerve stimulation (SNS), and intradetrusor botulinum toxin A (BTX) among privately insured patients and examine factors associated with their use. Researchers distinguished patients who had undergone third-line OAB treatments based on procedure codes applying MarketScan claims (2015-2017). Researchers conducted multivariable logistic regression models to calculate correlations between pertinent factors with receipt of PTNS and SNS relative to BTX and correlations between provider type and practice location with each treatment modality. They included a total of 7383 patients (mean age 50.9) in this cohort. PTNS was applied infrequently among patients receiving third-line OAB treatment. This study's findings demonstrate that PTNS utilization was concentrated within urban areas, and among older patients and those covered by cost-conscious health maintenance organizations.